- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00336596
Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion
25. april 2007 oppdatert av: University of Zurich
Transcranial Ultrasound Enhanced Thrombolysis (TRUST)
The purpose of the present, randomized, controlled multicenter phase III trial is to investigate the safety and efficacy of continuous 1-hour insonation of occluded middle cerebral artery with 2 MHz TCCS in stroke patients treated with intravenous tissue plasminogen activator (t-PA) within 3 hours after symptom onset.
Studieoversikt
Status
Ukjent
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Thrombolysis with intravenous(iv) tissue plasminogen activator (t-PA) is the only effective and approved therapy for acute ischemic stroke.
The most frequent cause of ischemic stroke is thrombosis of the middle cerebral artery (MCA).
Preliminary in vitro, animal and human studies suggest that ultrasound accelerates thrombolysis induced by t-PA, and recanalization of acute MCA occlusion due to thrombolysis is an independent predictor of good clinical outcome.
Thus, insonation of an occluded MCA through the temporal bone in stroke patients who are treated with iv t-PA might enhance recanalization and improve clinical outcome.
The present prospective, randomized, controlled multicenter pilot study will investigate the safety and efficacy of continuous 1-hour insonation of the occluded MCA with 2 MHz transcranial color duplex sonography in patients with ischemic stroke treated with iv t-PA within 3 hours after symptom onset.
It is planned to randomize 400 patients in 6 Swiss centers during an enrolment period of 33 months with an individual follow up of 3 months.
The study endpoints include safety and efficacy assessments.
The primary safety endpoint is to determine the rate of symptomatic intracranial hemorrhage (ICH) in both treatment groups.
The primary efficacy endpoint is to determine whether a good functional outcome (modified Rankin scale, mRs, score of 0-2) differs between both treatment groups.
Secondary endpoints include (1) asymptomatic ICH occuring during or within the first 24-48 hours after t-PA infusion, (2) early clinical recovery by 10 or more National Institute of Health Stroke Scale (NIHSS) points or dramatic recovery (total NIHSS score of 3 or less) at 24-48 hours after t-PA infusion, (3) mean mRS score at 90 days after t-PA infusion, (4) death occuring during the study period, and (5) recanalization at 24-48 hours after t-PA infusion.
Studietype
Intervensjonell
Registrering
400
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Aarau, Sveits
- Rekruttering
- Kantonsspital Aarau, Department of Neurology
-
Ta kontakt med:
- Hansjörg Hungerbühler, MD
- Telefonnummer: +41 62 838 66 75
- E-post: hansjoerg.hungerbuehler@ksa.ch
-
Hovedetterforsker:
- Hansjörg Hungerbühler, MD
-
Basel, Sveits
- Rekruttering
- University Hospital of Basel, Department of Neurology
-
Ta kontakt med:
- Stefan Engelter, MD
- Telefonnummer: +41 61 265 25 25
- E-post: sengelter@uhbs.ch
-
Hovedetterforsker:
- Philippe Lyrer, MD
-
Hovedetterforsker:
- Stefan Engelter, MD
-
Bern, Sveits
- Rekruttering
- University hospital of Bern, Department of Neurology
-
Ta kontakt med:
- Marcel Arnold, MD
- Telefonnummer: +41 31 632 33 32
- E-post: marcel.arnold@insel.ch
-
Hovedetterforsker:
- H.-P. Mattle, MD
-
Hovedetterforsker:
- Marcel Arnold, MD
-
Geneva, Sveits
- Rekruttering
- University Hospital of Geneva, Department of Neurology
-
Ta kontakt med:
- Roman Sztajzel, MD
- Telefonnummer: +41 22 372 83 10
- E-post: Roman.Sztajzel@hcuge.ch
-
Hovedetterforsker:
- Roman Sztajzel, MD
-
Lausanne, Sveits
- Rekruttering
- University Hospital of Lausanne, Department of Neurology
-
Ta kontakt med:
- Patrik Michel, MD
- Telefonnummer: +41 21 314 11 85
- E-post: patrik.michel@chuv.hospvd.ch
-
Hovedetterforsker:
- Patrik Michel, MD
-
Zurich, Sveits, 8091
- Rekruttering
- University Hospital of Zurich, Department of Neurology
-
Ta kontakt med:
- Ralf W Baumgartner, MD
- Telefonnummer: +41 1 255 56 86
- E-post: ralf.baumgartner@usz.ch
-
Ta kontakt med:
- Dimitrios Georgiadis, MD
- E-post: dimitrios.georgiadis@usz.ch
-
Hovedetterforsker:
- Ralf W Baumgartner, MD
-
Hovedetterforsker:
- Dimitrios Georgiadis, MD
-
Underetterforsker:
- Hakan Sarikaya, MD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- acute ischemic stroke in the MCA territory according to clinical and cranial computed tomography (CT) or cranial MR imaging (MRI) findings
- patient undergoing iv thrombolysis with t-PA within 3 hours after stroke onset
- Occlusion of sphenoidal (M1) or insular (M2) segment of the MCA at CT (CTA), MR (MRA) or catheter (CA) angiography
- appropriate temporal bony window without echocontrast agents for insonation with TCCS
- full functional independence prior to present stroke (mRS 0-1), use of a cane for walking due to comorbid condition is acceptable
- written informed consent, signed and dated by the subject (or subject's authorized representative, if allowed by local laws) and by the person obtaining the consent, indicating agreement to comply with all protocol-specific procedures
Exclusion Criteria:
- unconsciousness (more than 2 points on item 1a on NIHSS)
- history of intracranial hemorrhage, arteriovenous malformation or aneurysm
- severe cranio-cerebral trauma within the last 3 months
- symptoms of subarachnoidal hemorrhage
- time of symptom onset unclear
- large surgical intervention or trauma within the last 10 days
- expected survival below 90 days after iv t-PA treatment
- severe hepatic disease, esophageal varices, acute pancreatitis
- septic embolism, endocarditis, pericarditis after myocardial infarction
- pregnancy or childbirth within the last 30 days or nursing mothers
- history of hemorrhagic diathesis or coagulopathy
- untreatable increase of arterial blood pressure (>185mmHg systolic, >110mmHg diastolic)
- intracranial hemorrhage, arteriovenous malformations or aneurysm at brain imaging
- thrombocytes <100'000 per microliter
- international normalized ratio (INR)>1.7 or partial thromboplastin time (PTT) prolongated
- serum glucose <2.7mmol/l or >22.2mmol/l
- severe renal insufficiency or other contraindications against CT-contrast agents
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
|---|
|
Symptomatic intracranial hemorrhage (safety)
|
|
Functional outcome (efficacy)
|
Sekundære resultatmål
Resultatmål |
|---|
|
Asymptomatic intracranial hemorrhage 24-48 hours after t-PA infusion
|
|
Early clinical recovery by 10 or more NIHSS points or dramatic recovery (total NIHSS 3 or less)at 24-48 hours after t-PA infusion
|
|
Mean mRS score at 90 days after t-PA infusion
|
|
Death occurring during study period
|
|
Recanalization at 24-48 hours after t-PA infusion
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Studiestol: Ralf W Baumgartner, MD, University Hospital of Zurich, Department of Neurology, Zurich, Switzerland
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. juni 2006
Studiet fullført (Forventet)
1. juni 2009
Datoer for studieregistrering
Først innsendt
13. juni 2006
Først innsendt som oppfylte QC-kriteriene
13. juni 2006
Først lagt ut (Anslag)
14. juni 2006
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
27. april 2007
Siste oppdatering sendt inn som oppfylte QC-kriteriene
25. april 2007
Sist bekreftet
1. april 2007
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Iskemi
- Patologiske prosesser
- Nekrose
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Cerebrovaskulære lidelser
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Embolisme og trombose
- Hjerneiskemi
- Infarkt
- Slag
- Hjerneinfarkt
- Cerebrale arterielle sykdommer
- Intrakranielle arterielle sykdommer
- Intrakraniell emboli og trombose
- Tromboemboli
- Cerebralt infarkt
- Embolisme
- Trombose
- Infarkt, midtre cerebral arterie
- Intrakraniell emboli
Andre studie-ID-numre
- E-031/2004
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .